16. Approaches to Delivering RNAi Therapeutics that Target Hepatitis B Virus

  1. Kun Cheng2 and
  2. Ram I. Mahato3
  1. Carol Crowther,
  2. Mohube Betty Mowa,
  3. Abdullah Ely and
  4. Patrick Arbuthnot

Published Online: 26 APR 2013

DOI: 10.1002/9781118610749.ch16

Advanced Delivery and Therapeutic Applications of RNAi

Advanced Delivery and Therapeutic Applications of RNAi

How to Cite

Crowther, C., Mowa, M. B., Ely, A. and Arbuthnot, P. (2013) Approaches to Delivering RNAi Therapeutics that Target Hepatitis B Virus, in Advanced Delivery and Therapeutic Applications of RNAi (eds K. Cheng and R. I. Mahato), John Wiley and Sons, Ltd, Chichester, UK. doi: 10.1002/9781118610749.ch16

Editor Information

  1. 2

    School of Pharmacy, University of Missouri-Kansas City, USA

  2. 3

    Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, USA

Author Information

  1. Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty University of the Witwatersrand South Africa

Publication History

  1. Published Online: 26 APR 2013
  2. Published Print: 10 JUN 2013

ISBN Information

Print ISBN: 9781119976868

Online ISBN: 9781118610749

SEARCH

Keywords:

  • hepatitis B virus;
  • RNA interference;
  • gene therapy;
  • nonviral vectors;
  • viral vectors

Summary

Chronic hepatitis B virus (HBV) infection is a major cause of liver disease and treatment and currently available therapies are only partially effective. RNA interference has been used successfully to counter HBV replication and has potential therapeutic application. The utility of nonviral and viral vectors for delivering RNAi effecters and their relevance for the development of RNAi-based HBV treatment are discussed.